Loading
A same-day PET tracer could replace the two-day, low-resolution MIBG scan children now undergo repeatedly.
Children with neuroblastoma repeatedly undergo 123I-MIBG scintigraphy, a two-day, low-resolution scan, and this idea proposes replacing it with same-day 18F-MFBG PET. 18F-meta-fluorobenzylguanidine uses the same norepinephrine-transporter biology as MIBG but gains PET resolution and 18F logistics, needs no sedation across two days, and early data show higher lesion detection. The hypothesis is that MFBG PET/CT detects more lesions than MIBG SPECT with equal specificity, and that Curie-type scoring on MFBG predicts outcome at least as well. Prospective paired comparisons are under way at MSK and in COG imaging studies and an NDA is in progress; at an early clinical stage, it sits within the paediatric oncology roadmap alongside the MIBG theranostics and PET records.
Shares MIBG imaging and 131I-MIBG therapy, Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma.
Shares Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma.
Shares MIBG imaging and 131I-MIBG therapy, High-risk neuroblastoma, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric).
Shares Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares High-risk neuroblastoma, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric).
Shares MIBG imaging and 131I-MIBG therapy, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma, Neuroblastoma (paediatric).